ArticleJournal of inflammation research2026
Yi-qi-hua-yu-jie-du Decoction Inhibits Gastric Cancer Progression by Inducing Tumor-Associated Macrophage Polarization via Modulating PP2A Enzyme Activity to Mediate the PI3K/AKT/NF-κB Axis.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer (GC) is a major global malignancy with high recurrence and metastasis rates. Yi-qi-hua-yu-jie-du decoction (YJD) demonstrates clinical efficacy in reducing these risks. However, its mechanism of modulating tumor-associated macrophages (TAMs) in GC remains unclear. This study aimed to investigate YJD's inhibitory effects via TAM polarization and uncover the underlying mechanisms. Methods: Network pharmacology identified key targets/pathways for YJD's action on TAMs in GC, with binding affinities assessed. A tumor cell-macrophage co-culture system was developed to investigate YJD's impacts on TAM phenotype conversion, malignant cell proliferation, apoptotic induction, and epithelial-mesenchymal transition (EMT) progression. BALB/c nude mice GC xenografts models were established to assess YJD's in vivo antitumor activity, safety profile, and TME modulation. Techniques including cell viability assays, Western blotting, flow cytometry, wound healing assays, PP2A activity assays, immunofluorescence, and immunohistochemistry were employed to validate the proposed mechanism. Results: YJD active components exhibit high-affinity binding sites with the PP2A catalytic subunit. Key enriched pathways for YJD-regulated macrophage polarization included PI3K-AKT and NF-κB. YJD significantly inhibited tumor growth, reduced M2-type TAMs in vivo, and exhibited a favorable safety profile. In vitro, YJD promoted M1 polarization, inhibited gastric cells proliferation, induced apoptosis, and reversed EMT. Mechanistically, YJD enhanced PP2A activity, suppressed the PI3K/AKT axis, and modulated NF-κB signaling to drive M1 polarization-effects blocked by a PP2A inhibitor. Conclusion: YJD suppresses GC progression through PP2A-dependent modulation of the PI3K/AKT/NF-κB axis, shifting TAM polarization toward the anti-tumor M1 phenotype. This elucidates the pharmacological basis of YJD's anti-tumor effects and supports its clinical potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.